Endocrinology of the Aging Prostate: Current Concepts

被引:62
作者
Cannarella, Rossella [1 ]
Condorelli, Rosita A. [1 ]
Barbagallo, Federica [1 ]
La Vignera, Sandro [1 ]
Calogero, Aldo E. [1 ]
机构
[1] Univ Catania, Dept Clin & Expt Med, Catania, Italy
来源
FRONTIERS IN ENDOCRINOLOGY | 2021年 / 12卷
关键词
low urinary tract symptoms; metabolic syndrome; aging; insulin; male PCOS-equivalent; benign prostate hyperplasia; POLYCYSTIC-OVARY-SYNDROME; URINARY-TRACT SYMPTOMS; GROWTH-FACTOR-I; METABOLIC SYNDROME; TESTOSTERONE THERAPY; CANCER; MEN; DEFICIENCY; ANDROGENS; CELLS;
D O I
10.3389/fendo.2021.554078
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Benign prostate hyperplasia (BPH), one of the most common diseases in older men, adversely affects quality-of-life due to the presence of low urinary tract symptoms (LUTS). Numerous data support the presence of an association between BPH-related LUTS (BPH-LUTS) and metabolic syndrome (MetS). Whether hormonal changes occurring in MetS play a role in the pathogenesis of BPH-LUTS is a debated issue. Therefore, this article aimed to systematically review the impact of hormonal changes that occur during aging on the prostate, including the role of sex hormones, insulin-like growth factor 1, thyroid hormones, and insulin. The possible explanatory mechanisms of the association between BPH-LUTS and MetS are also discussed. In particular, the presence of a male polycystic ovarian syndrome (PCOS)-equivalent may represent a possible hypothesis to support this link. Male PCOS-equivalent has been defined as an endocrine syndrome with a metabolic background, which predisposes to the development of type II diabetes mellitus, cardiovascular diseases, prostate cancer, BPH and prostatitis in old age. Its early identification would help prevent the onset of these long-term complications.
引用
收藏
页数:13
相关论文
共 157 条
[1]   Metabolic Syndrome and Benign Prostatic Hyperplasia: Evidence of a Potential Relationship, Hypothesized Etiology, and Prevention [J].
Abdollah, Firas ;
Briganti, Alberto ;
Suardi, Nazareno ;
Castiglione, Fabio ;
Gallina, Andrea ;
Capitanio, Umberto ;
Montorsi, Francesco .
KOREAN JOURNAL OF UROLOGY, 2011, 52 (08) :507-516
[2]   Insulin-like growth factor-1 deficiency and metabolic syndrome [J].
Aguirre, G. A. ;
Rodriguez De Ita, J. ;
de la Garza, R. G. ;
Castilla-Cortazar, I. .
JOURNAL OF TRANSLATIONAL MEDICINE, 2016, 14
[3]   Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease [J].
Ahearn, Thomas U. ;
Peisch, Sam ;
Pettersson, Andreas ;
Ebot, Ericka M. ;
Zhou, Cindy Ke ;
Graff, Rebecca E. ;
Sinnott, Jennifer A. ;
Fazli, Ladan ;
Judson, Gregory L. ;
Bismar, Tarek A. ;
Rider, Jennifer R. ;
Gerke, Travis ;
Chan, June M. ;
Fiorentino, Michelangelo ;
Flavin, Richard ;
Sesso, Howard D. ;
Finn, Stephen ;
Giovannucci, Edward L. ;
Gleave, Martin ;
Loda, Massimo ;
Li, Zhe ;
Pollak, Michael ;
Mucci, Lorelei A. .
CARCINOGENESIS, 2018, 39 (12) :1431-1437
[4]   Androgenetic alopecia and risk of prostate cancer: A systematic review and meta-analysis [J].
Amoretti, Aline ;
Laydner, Humberto ;
Bergfeld, Wilma .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 68 (06) :937-943
[5]   Androgenetic alopecia as an early marker of benign prostatic hyperplasia [J].
Arias-Santiago, Salvador ;
Angel Arrabal-Polo, Miguel ;
Buendia-Eisman, Agustin ;
Arrabal-Martin, Miguel ;
Teresa Gutierrez-Salmeron, Maria ;
Sierra Giron-Prieto, Maria ;
Jimenez-Pacheco, Antonio ;
Calonje, Jaime Eduardo ;
Naranjo-Sintes, Ramon ;
Zuluaga-Gomez, Armando ;
Serrano Ortega, Salvio .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (03) :401-408
[6]   STROMAL AND EPITHELIAL-CELLS FROM RAT VENTRAL PROSTATE DURING ANDROGEN DEPRIVATION AND ESTROGEN-TREATMENT .2. REGULATION OF TRANSCRIPTION [J].
BACHER, M ;
RAUSCH, U ;
GOEBEL, HW ;
POLZAR, B ;
MANNHERZ, HG ;
AUMULLER, G .
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY, 1993, 101 (02) :78-86
[7]   Loss of ERβ expression as a common step in estrogen-dependent tumor progression [J].
Bardin, A ;
Boulle, N ;
Lazennec, G ;
Vignon, F ;
Pujol, P .
ENDOCRINE-RELATED CANCER, 2004, 11 (03) :537-551
[8]   Dihydrotestosterone and the concept of 5α-reductase inhibition in human benign prostatic hyperplasia [J].
Bartsch, G ;
Rittmaster, RS ;
Klocker, H .
EUROPEAN UROLOGY, 2000, 37 (04) :367-380
[9]  
Bayar G, 2017, TURK J UROL, V43, P289, DOI 10.5152/tud.2017.35467
[10]  
BELANGER A, 1994, J CLIN ENDOCR METAB, V79, P1086